Table 4.
Lesion Outcomes Among Patients Undergoing Endovascular Interventions.
| Statin | No Statin | Adjusted HR | |
|---|---|---|---|
| Femoropopliteal Lesions | |||
| Primary Patency | 55% | 53% | 0.87 (0.50–1.50) |
| Primary Assisted Patency | 73% | 67% | 0.62 (0.31–1.30) |
| Secondary Patency | 84% | 69% | 0.50 (0.22–1.30) |
| Infrapopliteal Lesions | |||
| Primary Patency | 62% | 52% | 0.84 (0.50–1.42) |
| Primary Assisted Patency | 78% | 57% | 0.50 (0.26–0.96) |
| Secondary Patency | 83% | 59% | 0.45 (0.22–0.89) |
Abbreviations: HR, hazard ratio. Adjusted HR includes multivariable adjustment for lesion length, proximal vessel reference diameter, diabetes, gender, smoking status, and estimated glomerular filtration rate. Femoropopliteal lesions were also adjusted for stent placement.